New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 29, 2014
07:23 EDTBMYBristol-Myers acquires iPerian for $175M
Bristol-Myers Squibb and iPierian announced Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies. The acquisition gives Bristol-Myers Squibb full rights to iPierianís asset IPN007, a preclinical monoclonal antibody that represents a new approach to treat progressive supranuclear palsy and other Tauopathies, and has the potential to commence Phase 1 clinical trials by early FY15. Under the terms of the agreement, Bristol-Myers Squibb has acquired all of iPierianís issued and outstanding shares of capital stock and all common stock equivalents in an all cash transaction for a purchase price of $175M, with the potential for additional development and regulatory milestone payments totaling $550M, along with future royalties on net sales. The transaction is expected to be accounted for as an asset acquisition for Bristol-Myers Squibb resulting in a $175M charge during 2Q14.
News For BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
11:31 EDTBMYLion Biotechnologies TIL combo data an 'important' positive, says Piper Jaffray
After Lion Biotechnologies (LBIO) announced the report of positive results from a pilot trial of tumor infiltrating lymphocytes, or TIL, in combination with Bristol-Myers' (BMY) Yervoy in patients with metastatic melanoma, Piper Jaffray noted that the success rate for receiving TIL combo treatment was significantly higher than the prior result for TIL monontherapy. Piper said this fact highlights the combo approach may drive significantly broader application of TIL than it initially expected and the firm reiterated its Overweight rating and $21 price target on Lion shares.
March 26, 2015
07:30 EDTBMYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
March 20, 2015
07:55 EDTBMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use